Phosphodiesterase 5 inhibitor

Known as: Phosphodiesterase V Inhibitor, Inhibitors, PDE5, PDE 5 Inhibitors 
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
National Institutes of Health

Related topics

Related topics

11 relations
In Bloodaspects of radiation effectscGMP Phosphodiesterase Inhibitorchemical synthesis
(More)

Broader (1)

Phosphodiesterase 5 Inhibitor [EPC]

Narrower (5)

Sildenafil citratemirodenafiltadalafiludenafil
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model.
Memory loss, synaptic dysfunction, and accumulation of amyloid beta-peptides (A beta) are major hallmarks of Alzheimer's disease… (More)
Is this relevant?
2009
2009
Effect of phosphodiesterase-5 inhibitor on hearing.
OBJECTIVE Following a report of sudden hearing loss in a patient taking phosphodiesterase type 5 inhibitor, and a Food and Drug… (More)
  • figure 1
  • figure 2
  • table I
  • table II
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
The pulmonary vascular bed is both a source of and target for a number of vasoactive factors. Among the most important for… (More)
  • figure 1
  • table 1
  • table 3
  • table 4
Is this relevant?
2007
2007
The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway.
cGMP-degrading pathways have received little attention in the context of angiogenesis. In the present study we set out to… (More)
Is this relevant?
2007
2007
Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms.
BACKGROUND Chronic prostatitis is a common urological complaint without clearly defined causation or definitive treatment… (More)
Is this relevant?
2006
2006
PHOSPHODIESTERASE-5 INHIBITORS FOR ERECTILE DYSFUNCTION
  • David Kleynberg
  • 2006
Volume 21, Issue 11, August 2006 1 the initial manifestation of underlying vascular disease. Regardless of the etiology… (More)
  • table 1
  • table 2
  • table 3
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Effect of regular phosphodiesterase type 5 inhibition in hypertension.
There are no published controlled clinical trials of regular phosphodiesterase type 5 inhibitor therapy as a long-term treatment… (More)
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.
Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of pulmonary hypertension. This study… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
BACKGROUND Phosphodiesterase type 5 (PDE5) is a novel therapeutic target for the treatment of pulmonary hypertension. This study… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
1999
Review
1999
Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney.
Investigations of recent years revealed that isozymes of cyclic-3', 5'-nucleotide phosphodiesterase (PDE) are a critically… (More)
Is this relevant?